Pembrolizumab - branded as Keytruda - will be funded from October 1, 2024, for eligible people with advanced triple-negative ...

Second treatment, Bevacizumab is used on liver and ovarian cancer - and would be funded by next April. Pharmac Chief Medical Officer, David Hughes, says offering them will have a wide effect, and ...

Every day eight New Zealanders are diagnosed with a form of blood cancer, including leukaemia, lymphoma, or * Leukaemia and ...

Bevacizumab is currently used in hospitals to treat some non-cancer conditions, but it can also be used for different types of cancer, for example, liver and ovarian cancer. Pharmac has told suppliers ...

The Associate Health Minister’s letter of expectations for Pharmac includes things that could fundamentally alter its core ...

Associate Health Minister with responsibility for Pharmac David Seymour has welcomed the increased availability of medicines for Kiwis resulting from the Government’s increased investment in Pharmac.